These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 29105111)

  • 1. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
    Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVES.
    Chen JY; Ren Y; Yan P; Belina ME; Chung RT; Butt AA
    J Viral Hepat; 2018 Jul; 25(7):825-833. PubMed ID: 29478294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus.
    Xu F; Moorman AC; Tong X; Gordon SC; Rupp LB; Lu M; Teshale EH; Spradling PR; Boscarino JA; Trinacty CM; Schmidt MA; Holmberg SD; ; Holmberg SD; Teshale EH; Spradling PR; Moorman AC; Xing J; Tong X; Xu F; Gordon SC; Nerenz DR; Lu M; Lamerato L; Wang Y; Rupp LB; Akkerman N; Oja-Tebbe N; Zhang T; Li J; Sitarik A; Larkin D; Boscarino JA; Daar ZS; Curry PJ; Smith RE; Vijayadeva V; Parker JV; Schmidt MA; Donald JL; Keast EM
    Clin Infect Dis; 2016 Feb; 62(3):289-297. PubMed ID: 26417034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C.
    Ng V; Saab S
    Clin Gastroenterol Hepatol; 2011 Nov; 9(11):923-30. PubMed ID: 21699815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
    Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
    Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection.
    Zavaglia C; Silini E; Mangia A; Airoldi A; Piazzolla V; Vangeli M; Stigliano R; Foschi A; Mazzarelli C; Tinelli C
    Liver Int; 2014 Aug; 34(7):e308-16. PubMed ID: 24529078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis progression in hepatitis C virus infection after seroconversion.
    Butt AA; Yan P; Lo Re V; Rimland D; Goetz MB; Leaf D; Freiberg MS; Klein MB; Justice AC; Sherman KE;
    JAMA Intern Med; 2015 Feb; 175(2):178-85. PubMed ID: 25485735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
    Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
    Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
    Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
    Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
    Park H; Wang W; Henry L; Nelson DR
    Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of hepatitis C virus infection in a large national seroconversion cohort in the direct-acting antiviral agent era: Results from ERCHIVES.
    Butt AA; Yan P;
    J Viral Hepat; 2021 Jun; 28(6):916-924. PubMed ID: 33763947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    Kramer JR; El-Serag HB; Taylor TJ; White DL; Asch SM; Frayne SM; Cao Y; Smith DL; Kanwal F
    J Viral Hepat; 2017 Nov; 24(11):955-965. PubMed ID: 28815822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
    Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    J Viral Hepat; 2016 Sep; 23(9):687-96. PubMed ID: 27040447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.